VIVUS, Inc. (VVUS): Price and Financial Metrics


VIVUS, Inc. (VVUS)

Today's Latest Price: $0.47 USD

0.05 (-10.29%)

Updated Jul 16 7:41pm

Add VVUS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

VVUS Stock Summary

  • VVUS has a higher market value than merely 4.35% of US stocks; more precisely, its current market capitalization is $8,344,214.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -3.65 for Vivus Inc; that's greater than it is for merely 3.86% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VVUS comes in at 585.71% -- higher than that of 98.9% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Vivus Inc, a group of peers worth examining would be KRA, SGMS, ITGR, NH, and NAV.
  • VVUS's SEC filings can be seen here. And to visit Vivus Inc's official web site, go to www.vivus.com.

VVUS Stock Price Chart Interactive Chart >

Price chart for VVUS

VVUS Price/Volume Stats

Current price $0.47 52-week high $4.75
Prev. close $0.52 52-week low $0.44
Day low $0.46 Volume 2,026,800
Day high $0.50 Avg. volume 1,441,313
50-day MA $1.00 Dividend yield N/A
200-day MA $2.08 Market Cap 8.33M

VIVUS, Inc. (VVUS) Company Bio


VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company was founded in 1991 and is based in Mountain View, California.


VVUS Latest News Stream


Event/Time News Detail
Loading, please wait...

VVUS Latest Social Stream


Loading social stream, please wait...

View Full VVUS Social Stream

Latest VVUS News From Around the Web

Below are the latest news stories about Vivus Inc that investors may wish to consider to help them evaluate VVUS as an investment opportunity.

Vivus moves closer to emerging from bankruptcy

Vivus (VVUS) plummets 26% premarket after completing the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma will take 100% ownership of the company (the “Prepackaged Plan”), ahead of its Chapter 11 filing.The company solicited IEH as the only holder of claims and has received IEH’s voting in favor of...

Seeking Alpha | July 8, 2020

The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma...

Benzinga | July 8, 2020

VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing. The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged Plan―and has received IEH’s ballots voting in favor of the Prepackaged Plan in accordance with the amended and restated Restructuring Support Agreement executed by the Company and IEH on July 6, 2020.

Yahoo | July 7, 2020

VVUS: Enterprise Valuation Update

By John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT Debt Restructuring In May 2013, Vivus, Inc. (NASDAQ:VVUS) closed offerings of $250 million of 4.5% convertible debt that became due in May 2020. The conversion rate of the notes is 6.73038 per $1,000 of face value leaving them well out of the money and unable to convert. Without conversion, the notes remained as debt and

Yahoo | June 10, 2020

Vivus files for equity offering

VIVUS (VVUS) has filed a preliminary prospectus for a public offering of stock and warrants of up to ~$186M. Prices, volumes and terms have yet to be determined.Shares down 3% premarket on light volume....

Seeking Alpha | June 9, 2020

Read More 'VVUS' Stories Here

VVUS Price Returns

1-mo N/A
3-mo N/A
6-mo -58.04%
1-year -82.91%
3-year -92.86%
5-year -96.59%
YTD -82.72%
2019 21.97%
2018 -55.67%
2017 -56.26%
2016 12.75%
2015 -64.58%

Continue Researching VVUS

Here are a few links from around the web to help you further your research on Vivus Inc's stock as an investment opportunity:

Vivus Inc (VVUS) Stock Price | Nasdaq
Vivus Inc (VVUS) Stock Quote, History and News - Yahoo Finance
Vivus Inc (VVUS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8976 seconds.